-
Jan 6, 2025 | 
nature.com | Eric V. Li |Sai Kumar |Jonathan Aguiar |Clayton Neill |Edward Schaeffer |Ashley Ross
AbstractTraditional nomograms can inform the presence of extraprostatic extension (EPE) but not laterality, which remains important for surgical planning, and have not fully incorporated multiparametric MRI data. We evaluated predictors of side-specific EPE on surgical pathology including MRI characteristics and developed side-specific EPE risk calculators.
-
Jun 9, 2024 | 
nature.com | Eric Li |Mohammad R. Siddiqui |Jonathan Aguiar |Sai Kumar |Edward Schaeffer
AbstractMultiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual prostate biopsy, and subsequent detection of clinically significant prostate cancer (csPCa, Grade Group ≥2).
-
May 22, 2024 | 02375-3/abstract?rss=yes&sz=64)
europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more
Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.
-
Apr 26, 2024 | 02317-0/fulltext?rss=yes&sz=64)
europeanurology.com | Jim C. Hu |Andrew J. Vickers |Edward Schaeffer
We appreciate the thoughtful comments from Rosen et al on our article [[1]Hu JC, Assel M, Allaf ME, et al. Transperineal versus transrectal magnetic resonance imaging–targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015. ] and other randomized trials comparing transrectal to transperineal prostate biopsy.
-
Apr 26, 2024 | 02314-5/fulltext?rss=yes&sz=64)
europeanurology.com | Jim C. Hu |Andrew J. Vickers |Edward Schaeffer
We agree with the points made by Chiu et al [[1]Chiu PKF, Wu X, Gandaglia G, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond statistical significance: unveiling the advantages of transperineal versus transrectal prostate biopsies. Eur Urol. In press. ] in their Platinum Priority editorial on our article [[2]Hu JC, Assel M, Allaf ME, et al.
-
Apr 25, 2024 | 02319-4/fulltext?rss=yes&sz=64)
europeanurology.com | Jim C. Hu |Edward Schaeffer |Andrew J. Vickers
We are grateful for the thoughtful comments from Dr. Giannakodimos on our article [[1]Hu JC, Assel M, Allaf ME, et al. Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015. ] and the opportunity to reply.
-
Apr 9, 2024 | 02134-1/fulltext?rss=yes&sz=64)
europeanurology.com | Jim C. Hu |Andrew J. Vickers |Edward Schaeffer
We thank Marra et al for their laudatory comments on our study [[1]Hu JC, Assel M, Allaf ME, et al. Transperineal versus transrectal magnetic resonance imaging – targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015. ], and we welcome the opportunity to address the thoughtful points they presented.
-
Apr 9, 2024 | 02134-1/abstract&sz=64)
europeanurology.com | Jim C. Hu |Andrew J. Vickers |Edward Schaeffer
We thank Marra et al for their laudatory comments on our study [ 1 Hu JC, Assel M, Allaf ME, et al. Transperineal versus transrectal magnetic resonance imaging – targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol. 2024;86:61–68. ], and we welcome the opportunity to address the thoughtful points they presented.
-
Jan 7, 2024 | 
nature.com | Christina Yu |James Parrott |Edward Schaeffer |Vishal Kothari |Sarki A. Abdulkadir |Mihai Ioan Truica | +3 more
AbstractHeterogeneous response to Enzalutamide, a second-generation androgen receptor signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) management. Genome-wide systems investigation of mechanisms that govern Enzalutamide resistance promise to elucidate markers of heterogeneous treatment response and salvage therapies for CRPC patients.
-
Mar 27, 2023 | 
nature.com | Edward Schaeffer |Mohammad R. Siddiqui |Ashorne K. Mahenthiran
Author notesThese authors contributed equally: Mohammad R. Siddiqui, Eric V. Li.Authors and AffiliationsDepartment of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAMohammad R. Siddiqui, Eric V. Li, Sai K. S. R. Kumar, Anna Busza, Jasmine S. Lin, Ashorne K. Mahenthiran, Jonathan A. Aguiar, Parth V. Shah, Brandon Ansbro, Jordan M. Rich, Mary-Kate Keeter, Quan Mai, Edward M. Schaeffer, Hiten D. Patel & Ashley E.
